Key facts
- Atantares’s last known valuation is $14.5M (Jul 2025).
- It has raised $28.0M; the latest was Later Stage VC in Jan 2026.
- Notable investors include US National Science Foundation, Qiming Venture Partners, Aramco Ventures, Frees Fund, Leader Venture Capital — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Atantares
- ·The full record, as it builds
Funding rounds
No funding rounds for Atantares are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atantares
Developer of precision medicines and smart diagnostic devices designed to transform disease management across hematology, cardiology, neurology and cancer. The company offers a coagulation device that helps in monitoring specific drugs or blood products, using coagulation assays that monitor platelet function tests, clotting times, and viscoelasticity with a proprietary biochip platform and chimeric antigen receptor, thereby enabling the next generation of precision medicine by fusing biochips and AI technologies.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2017
- Employees
- 60
- Website
- atantares.com/
- Ownership
- Privately Held (backing)
Atantares doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atantares shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atantares in its N-PORT filings yet. We sweep new filings monthly.